Have you been affected by bladder cancer?
Southampton Clinical Trials Unit wants your views on a proposed trial exploring skin side effects from bladder cancer treatment.
👉 forms.cloud.microsoft/e/Qs3D0T194A
Your voice can help shape future research.
#BladderCancer #PatientVoice
Southampton Clinical Trials Unit wants your views on a proposed trial exploring skin side effects from bladder cancer treatment.
👉 forms.cloud.microsoft/e/Qs3D0T194A
Your voice can help shape future research.
#BladderCancer #PatientVoice
November 5, 2026 at 6:53 PM
Have you been affected by bladder cancer?
Southampton Clinical Trials Unit wants your views on a proposed trial exploring skin side effects from bladder cancer treatment.
👉 forms.cloud.microsoft/e/Qs3D0T194A
Your voice can help shape future research.
#BladderCancer #PatientVoice
Southampton Clinical Trials Unit wants your views on a proposed trial exploring skin side effects from bladder cancer treatment.
👉 forms.cloud.microsoft/e/Qs3D0T194A
Your voice can help shape future research.
#BladderCancer #PatientVoice
Bladder Cancer on the Rise in Younger Women #BladderCancer #cancer #MegaDoctorNews #RioGrandeValley #YoungWomenBladderCancer https://megadoctornews.com/bladder-cancer-on-the-rise-in-younger-women/
Bladder Cancer on the Rise in Younger Women
“The four-to-one ratio is no longer true when we start looking at the younger patients. What we have started seeing is 30% of all bladder cancers are now in females, which is incredibly interesting. And we know that there is some kind of pathology happening that we don’t quite understand yet,” said Laura Bukavina, MD, MPH, urologic oncologist at Cleveland Clinic.
megadoctornews.com
November 6, 2026 at 4:43 PM
Bladder Cancer on the Rise in Younger Women #BladderCancer #cancer #MegaDoctorNews #RioGrandeValley #YoungWomenBladderCancer https://megadoctornews.com/bladder-cancer-on-the-rise-in-younger-women/
Drs Komal Jhaveri and Roberto Iacovelli are joining our collaborators at COR2ED at ESMO 2026 to share their thoughts on the latest data presented at the meeting on #BreastCancer and in #ProstateCancer and #BladderCancer
👉 Explore the coverage cor2ed.com/highlights-f...
👉 Explore the coverage cor2ed.com/highlights-f...
November 4, 2026 at 3:20 PM
Drs Komal Jhaveri and Roberto Iacovelli are joining our collaborators at COR2ED at ESMO 2026 to share their thoughts on the latest data presented at the meeting on #BreastCancer and in #ProstateCancer and #BladderCancer
👉 Explore the coverage cor2ed.com/highlights-f...
👉 Explore the coverage cor2ed.com/highlights-f...
Encouraging bladder cancer news! A trial found 75% of patients receiving enfortumab vedotin and pembrolizumab around surgery remained in remission after two years, compared with 39% receiving surgery alone.
www.hopkinsmedicine.org/news/article...
#BladderCancer #CancerResearch #TCSC
www.hopkinsmedicine.org/news/article...
#BladderCancer #CancerResearch #TCSC
A Proven Immunotherapy Approach for Bladder Cancer Is Also Likely Cost Effective
New research led by investigators at the Brady Urological Institute found that a combination treatment for people with bladder cancer significantly improved outcomes is also likely cost-effective.
www.hopkinsmedicine.org
November 4, 2026 at 10:45 AM
Encouraging bladder cancer news! A trial found 75% of patients receiving enfortumab vedotin and pembrolizumab around surgery remained in remission after two years, compared with 39% receiving surgery alone.
www.hopkinsmedicine.org/news/article...
#BladderCancer #CancerResearch #TCSC
www.hopkinsmedicine.org/news/article...
#BladderCancer #CancerResearch #TCSC
A urine test that reads RNA instead of DNA detected localized bladder cancer with 95% sensitivity at 90% specificity, beating urine tumor #BladderCancer #LiquidBiopsy #RNA #CancerResearch
https://freegardner.com/sci_scout/a-urine-test-that-reads-rna-not-dna-for-bladder-cancer.html
https://freegardner.com/sci_scout/a-urine-test-that-reads-rna-not-dna-for-bladder-cancer.html
A Urine Test That Reads RNA, Not DNA, for Bladder Cancer
A Urine Test That Reads RNA, Not DNA, for Bladder Cancer
freegardner.com
October 31, 2026 at 11:49 PM
A urine test that reads RNA instead of DNA detected localized bladder cancer with 95% sensitivity at 90% specificity, beating urine tumor #BladderCancer #LiquidBiopsy #RNA #CancerResearch
https://freegardner.com/sci_scout/a-urine-test-that-reads-rna-not-dna-for-bladder-cancer.html
https://freegardner.com/sci_scout/a-urine-test-that-reads-rna-not-dna-for-bladder-cancer.html
Join Drs Komal Jhaveri , Roberto Iacovelli and COR2ED for some great highlights from ESMO 2026 ! 👉 Explore the coverage cor2ed.com/highlights-f...
Dr Jhaveri provides insights on #BreastCancer data, while Dr Iacovelli reviews developments in #ProstateCancer and #BladderCancer
Dr Jhaveri provides insights on #BreastCancer data, while Dr Iacovelli reviews developments in #ProstateCancer and #BladderCancer
October 30, 2026 at 2:45 PM
Join Drs Komal Jhaveri , Roberto Iacovelli and COR2ED for some great highlights from ESMO 2026 ! 👉 Explore the coverage cor2ed.com/highlights-f...
Dr Jhaveri provides insights on #BreastCancer data, while Dr Iacovelli reviews developments in #ProstateCancer and #BladderCancer
Dr Jhaveri provides insights on #BreastCancer data, while Dr Iacovelli reviews developments in #ProstateCancer and #BladderCancer
Why ‘More Drugs’ Isn’t Always Better: VOLGA Trial Redefines #BladderCancer Care
#Podium2Screen from the #ESMO26 Presidential Session
Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: VOLGA
#Podium2Screen from the #ESMO26 Presidential Session
Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: VOLGA
October 28, 2026 at 11:30 AM
Why ‘More Drugs’ Isn’t Always Better: VOLGA Trial Redefines #BladderCancer Care
#Podium2Screen from the #ESMO26 Presidential Session
Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: VOLGA
#Podium2Screen from the #ESMO26 Presidential Session
Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: VOLGA
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TW6F2g !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TW6F2g !
#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
dlvr.it
October 29, 2026 at 3:58 PM
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TW6F2g !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TW6F2g !
#Oncology #SocialListening #LucidQuest
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TW6F2g !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TW6F2g !
#Oncology #SocialListening #LucidQuest
ASCO_GU_ 2025_Social_Media_Report.pdf
dlvr.it
October 29, 2026 at 3:58 PM
🚀 Dive into #ASCOGU25 buzz!
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TW6F2g !
#Oncology #SocialListening #LucidQuest
Top themes: #Efficacy 20%, #Data 19%, #ClinicalTrials 15%.
#ProstateCancer & #BladderCancer dominate, 75% positive vibes on new immunotherapy wins. 📊🩺
Download our full report http://dlvr.it/TW6F2g !
#Oncology #SocialListening #LucidQuest
www.cbsnews.com/pittsburgh/n... We have lost Donnie Iris to bladder cancer at the age of 83. He gave his last show in Pittsburgh on Sept 28, announced his retirement on Oct 9, and has now passed over. Ah Leah will forever be a classic. #DonnieIris #DonnieIrisDeath #BladderCancer #AhLeah #Musicsky
Donnie Iris, Pittsburgh music legend, dies
Donnie Iris, the Pittsburgh music legend behind "Ah! Leah!," has died.
www.cbsnews.com
October 27, 2026 at 1:07 AM
www.cbsnews.com/pittsburgh/n... We have lost Donnie Iris to bladder cancer at the age of 83. He gave his last show in Pittsburgh on Sept 28, announced his retirement on Oct 9, and has now passed over. Ah Leah will forever be a classic. #DonnieIris #DonnieIrisDeath #BladderCancer #AhLeah #Musicsky
Why does #immunotherapy work for some patients with #BladderCancer but not others?
On the latest #BreakthroughsPodcast, @joshmeeks.bsky.social discusses his research uncovering how immune cells influence treatment response. @nmurology.bsky.social
🔗 spr.ly/6001BHcT9Z
On the latest #BreakthroughsPodcast, @joshmeeks.bsky.social discusses his research uncovering how immune cells influence treatment response. @nmurology.bsky.social
🔗 spr.ly/6001BHcT9Z
Decoding the Immune Response in Early-Stage Bladder Cancer with Joshua Meeks, MD, PhD
In this episode, Joshua Meeks, MD, PhD, breaks down his recent research published in the Journal of Clinical Investigation and European Urology uncovering how the tumor microenvironment and immune cel...
spr.ly
October 27, 2026 at 4:20 PM
Why does #immunotherapy work for some patients with #BladderCancer but not others?
On the latest #BreakthroughsPodcast, @joshmeeks.bsky.social discusses his research uncovering how immune cells influence treatment response. @nmurology.bsky.social
🔗 spr.ly/6001BHcT9Z
On the latest #BreakthroughsPodcast, @joshmeeks.bsky.social discusses his research uncovering how immune cells influence treatment response. @nmurology.bsky.social
🔗 spr.ly/6001BHcT9Z
Smoking greatly increases bladder cancer risk. Toxins from cigarette smoke pass into your urine, exposing your bladder to harmful chemicals. Quitting helps protect your health. 💚
#BladderCancer #Stoptober #SmokeFree
#BladderCancer #Stoptober #SmokeFree
October 27, 2026 at 8:37 AM
Smoking greatly increases bladder cancer risk. Toxins from cigarette smoke pass into your urine, exposing your bladder to harmful chemicals. Quitting helps protect your health. 💚
#BladderCancer #Stoptober #SmokeFree
#BladderCancer #Stoptober #SmokeFree
Now enrolling! BCG (a bladder immunotherapy) is standard for non-muscle invasive bladder cancer. For cancer that returns after BCG, Alliance A032103 (GAIN) trial tests adding gemcitabine—a chemo drug—to BCG to prevent recurrence. Learn more: https://bit.ly/Alliance-GAIN-BCG #BladderCancer
October 26, 2026 at 4:00 PM
Now enrolling! BCG (a bladder immunotherapy) is standard for non-muscle invasive bladder cancer. For cancer that returns after BCG, Alliance A032103 (GAIN) trial tests adding gemcitabine—a chemo drug—to BCG to prevent recurrence. Learn more: https://bit.ly/Alliance-GAIN-BCG #BladderCancer
A #perioperative regimen for muscle-invasive #bladdercancer (MIBC) based on AstraZeneca's Imfinzi and Astellas/Pfizer's Padcev has improved survival in the #VOLGAstudy, but the jury is out on whether it will displace a rival, established alternative.
pharmaphorum.com/news/esmo26-...
pharmaphorum.com/news/esmo26-...
October 25, 2026 at 6:25 PM
A #perioperative regimen for muscle-invasive #bladdercancer (MIBC) based on AstraZeneca's Imfinzi and Astellas/Pfizer's Padcev has improved survival in the #VOLGAstudy, but the jury is out on whether it will displace a rival, established alternative.
pharmaphorum.com/news/esmo26-...
pharmaphorum.com/news/esmo26-...
ESMO26: Adding nivolumab to perioperative chemo shows no significant benefit in muscle invasive bladder cancer. Watch Prof Andrea Necchi discuss his study👉https://ow.ly/n5905100OnB @AndreaNecchi @MyUniSR #ESMO26 #BladderCancer #OncologyResearch
Adding nivolumab to perioperative chemo shows no significant benefit in muscle invasive bladder cancer - ecancer
Prof Andrea Necchi speaks to ecancer about the final analysis of the phase III CA017-078 trial, which compared neoadjuvant gemcitabine and cisplatin alone with
ow.ly
October 25, 2026 at 4:45 PM
ESMO26: Adding nivolumab to perioperative chemo shows no significant benefit in muscle invasive bladder cancer. Watch Prof Andrea Necchi discuss his study👉https://ow.ly/n5905100OnB @AndreaNecchi @MyUniSR #ESMO26 #BladderCancer #OncologyResearch
#ESMO26: Neoadjuvant enfortumab vedotin significantly improved event-free and overall survival when added to peri-operative durvalumab for muscle-invasive #BladderCancer (#MIBC) in the phase III VOLGA #ClinicalTrial
🔗 https://ow.ly/g7KY50ZZH4m
#InsightsbyESMO #ADC
🔗 https://ow.ly/g7KY50ZZH4m
#InsightsbyESMO #ADC
October 24, 2026 at 3:00 PM
#ESMO26: Neoadjuvant enfortumab vedotin significantly improved event-free and overall survival when added to peri-operative durvalumab for muscle-invasive #BladderCancer (#MIBC) in the phase III VOLGA #ClinicalTrial
🔗 https://ow.ly/g7KY50ZZH4m
#InsightsbyESMO #ADC
🔗 https://ow.ly/g7KY50ZZH4m
#InsightsbyESMO #ADC
AstraZeneca’s phase 3 VOLGA trial found lower hazards of an event and death with durvalumab plus enfortumab vedotin around surgery for patients unable or unwilling to take cisplatin.
#BladderCancer #VOLGATrial #Durvalumab #EnfortumabVedotin #Cisplatin #EventFreeSurvival
[AI]
#BladderCancer #VOLGATrial #Durvalumab #EnfortumabVedotin #Cisplatin #EventFreeSurvival
[AI]
Can This Regimen Change Bladder Cancer Care?
VOLGA reported improved event-free and overall survival with durvalumab and enfortumab vedotin, but FDA review and comparisons remain.
harava.news
October 25, 2026 at 12:13 PM
AstraZeneca’s phase 3 VOLGA trial found lower hazards of an event and death with durvalumab plus enfortumab vedotin around surgery for patients unable or unwilling to take cisplatin.
#BladderCancer #VOLGATrial #Durvalumab #EnfortumabVedotin #Cisplatin #EventFreeSurvival
[AI]
#BladderCancer #VOLGATrial #Durvalumab #EnfortumabVedotin #Cisplatin #EventFreeSurvival
[AI]
#ESMO26: No significant increase in event-free survival seen with peri-operative pembrolizumab or nivolumab in the KEYNOTE-866 or ENERGIZE #ClinicalTrials of resectable muscle-invasive #BladderCancer (#MIBC), as discussed by Yohann Loriot
🔗 https://ow.ly/I5X150ZZiBa
#InsightsbyESMO
🔗 https://ow.ly/I5X150ZZiBa
#InsightsbyESMO
October 23, 2026 at 1:30 PM
#ESMO26: No significant increase in event-free survival seen with peri-operative pembrolizumab or nivolumab in the KEYNOTE-866 or ENERGIZE #ClinicalTrials of resectable muscle-invasive #BladderCancer (#MIBC), as discussed by Yohann Loriot
🔗 https://ow.ly/I5X150ZZiBa
#InsightsbyESMO
🔗 https://ow.ly/I5X150ZZiBa
#InsightsbyESMO
@AndreaNecchi with phase 3 #ENERGIZE trial results — cis gem nivo vs cis gem in muscle invasive #bladdercancer. 10% path CR rate diff but no diff on EFS or OS. ctDNA (+) at baseline has poor prognosis.
@oncoalert #ESMO26 @myESMO
@oncoalert #ESMO26 @myESMO
October 23, 2026 at 11:54 AM
@AndreaNecchi with phase 3 #ENERGIZE trial results — cis gem nivo vs cis gem in muscle invasive #bladdercancer. 10% path CR rate diff but no diff on EFS or OS. ctDNA (+) at baseline has poor prognosis.
@oncoalert #ESMO26 @myESMO
@oncoalert #ESMO26 @myESMO
#JensBedke presents #Keynote866 trial cis/gem/pembro vs chemo/placebo in muscle invasive #bladdercancer — higher pathCR but misses on EFS and OS.
@oncoalert @esmo #ESMO26
@oncoalert @esmo #ESMO26
October 23, 2026 at 11:43 AM
#JensBedke presents #Keynote866 trial cis/gem/pembro vs chemo/placebo in muscle invasive #bladdercancer — higher pathCR but misses on EFS and OS.
@oncoalert @esmo #ESMO26
@oncoalert @esmo #ESMO26
ALSO IN THIS ISSUE
Swift genomic classification of #braintumors
#cfRNA urine test for #bladdercancer
#FIT sensitivity different in women vs men
sensitiveandspecific.substack.com/p/why-geneti...
#sensitiveandspecific #diagnostics #genomictesting #colorectalcancer #testsensitivity #cancerscreening
Swift genomic classification of #braintumors
#cfRNA urine test for #bladdercancer
#FIT sensitivity different in women vs men
sensitiveandspecific.substack.com/p/why-geneti...
#sensitiveandspecific #diagnostics #genomictesting #colorectalcancer #testsensitivity #cancerscreening
Why genetic tests for adults should include inherited cancer
Volume 14, Issue 15 | October 22, 2026
sensitiveandspecific.substack.com
October 23, 2026 at 2:00 AM
ALSO IN THIS ISSUE
Swift genomic classification of #braintumors
#cfRNA urine test for #bladdercancer
#FIT sensitivity different in women vs men
sensitiveandspecific.substack.com/p/why-geneti...
#sensitiveandspecific #diagnostics #genomictesting #colorectalcancer #testsensitivity #cancerscreening
Swift genomic classification of #braintumors
#cfRNA urine test for #bladdercancer
#FIT sensitivity different in women vs men
sensitiveandspecific.substack.com/p/why-geneti...
#sensitiveandspecific #diagnostics #genomictesting #colorectalcancer #testsensitivity #cancerscreening
Erdafitinib Price and Global Pharmaceutical Supply
Contact a pharmaceutical supplier to discuss product availability, and documentation.
www.oddwayinternational.com/erdafitinib-...
#Erdafitinib #ErdafitinibPrice #BladderCancer #CancerTreatment #Oncology #Pharmaceuticals #PharmaExport #B2BPharma
Contact a pharmaceutical supplier to discuss product availability, and documentation.
www.oddwayinternational.com/erdafitinib-...
#Erdafitinib #ErdafitinibPrice #BladderCancer #CancerTreatment #Oncology #Pharmaceuticals #PharmaExport #B2BPharma
October 21, 2026 at 7:40 AM
Erdafitinib Price and Global Pharmaceutical Supply
Contact a pharmaceutical supplier to discuss product availability, and documentation.
www.oddwayinternational.com/erdafitinib-...
#Erdafitinib #ErdafitinibPrice #BladderCancer #CancerTreatment #Oncology #Pharmaceuticals #PharmaExport #B2BPharma
Contact a pharmaceutical supplier to discuss product availability, and documentation.
www.oddwayinternational.com/erdafitinib-...
#Erdafitinib #ErdafitinibPrice #BladderCancer #CancerTreatment #Oncology #Pharmaceuticals #PharmaExport #B2BPharma
We have a winner! 🎉Congratulations to Claire T, who correctly guessed there were 40 red flags (sweets) in our jar at #BAUN2026
Several guessed correctly, but our random wheel picked Claire!
Your M&S gift voucher will be emailed to you shortly. Enjoy! 💚
#BladderCancer #ABCUK
Several guessed correctly, but our random wheel picked Claire!
Your M&S gift voucher will be emailed to you shortly. Enjoy! 💚
#BladderCancer #ABCUK
October 20, 2026 at 6:49 PM
We have a winner! 🎉Congratulations to Claire T, who correctly guessed there were 40 red flags (sweets) in our jar at #BAUN2026
Several guessed correctly, but our random wheel picked Claire!
Your M&S gift voucher will be emailed to you shortly. Enjoy! 💚
#BladderCancer #ABCUK
Several guessed correctly, but our random wheel picked Claire!
Your M&S gift voucher will be emailed to you shortly. Enjoy! 💚
#BladderCancer #ABCUK
For cisplatin-ineligible muscle-invasive #BladderCancer, perioperative #EnfortumabVedotin plus pembrolizumab with radical cystectomy was associated with improved survival and was cost-effective vs radical cystectomy alone over 10 years. ja.ma/4i9RHyG
October 20, 2026 at 4:42 PM
For cisplatin-ineligible muscle-invasive #BladderCancer, perioperative #EnfortumabVedotin plus pembrolizumab with radical cystectomy was associated with improved survival and was cost-effective vs radical cystectomy alone over 10 years. ja.ma/4i9RHyG
New #paper from our lab! Led by @jinhuigao.bsky.social in collab with Eleanor Stride’s lab in Oxford, we introduce MitoCap, a new tissue-penetrative chemotherapeutic treatment for #BladderCancer intended for intravesical delivery - tested in our human urothelial model!
tinyurl.com/4zp3n7bd
tinyurl.com/4zp3n7bd
Evaluation of a rapid-release mitomycin C-loaded porous microcapsule formulation (MitoCap) in a human urothelium-tumour model
Intravesical mitomycin C (MMC) is limited by short bladder exposure and incomplete delivery to residual tumour tissue. We developed MitoCap, a porous …
tinyurl.com
October 19, 2026 at 7:43 AM
New #paper from our lab! Led by @jinhuigao.bsky.social in collab with Eleanor Stride’s lab in Oxford, we introduce MitoCap, a new tissue-penetrative chemotherapeutic treatment for #BladderCancer intended for intravesical delivery - tested in our human urothelial model!
tinyurl.com/4zp3n7bd
tinyurl.com/4zp3n7bd